Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FABP6 | P51161 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | ROS1 | P08922 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599652 | 0.89 | ALDH1A1 (0.62) | MAPTALDH1A1GAAHSD17B10FABP6 | |
| SCHEMBL29469482 | 0.89 | ALDH1A1 (0.62) | MAPTALDH1A1GAAHSD17B10FABP6 | |
| Hydrochloric Acid SCHEMBL2360497 | 0.87 | ALDH1A1 (0.61) | MAPTALDH1A1GAAHSD17B10FABP6 | |
| SCHEMBL29429213 | 0.86 | FABP6 (0.45) | MAPTALDH1A1GAAHSD17B10FABP6 | |
| SCHEMBL17927862 | 0.86 | FABP6 (0.45) | MAPTALDH1A1GAAHSD17B10FABP6 | |
| SCHEMBL6373230 | 0.79 | MAPT (0.50) | MAPTALDH1A1GAAHSD17B10FABP6 | |
| SCHEMBL31451377 | 0.79 | ALDH1A1 (0.80) | MAPTALDH1A1GAAHSD17B10PDE3B | |
| SCHEMBL14924444 | 0.79 | ALDH1A1 (0.80) | MAPTALDH1A1GAAHSD17B10PDE3B | |
| SCHEMBL20612394 | 0.79 | MAPT (0.50) | MAPTALDH1A1GAAHSD17B10PDE3B | |
| SCHEMBL17937404 | 0.78 | ALDH1A1 (0.41) | MAPTALDH1A1GAAHSD17B10FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20220227699-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| WO-2020228436-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-10308628-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180057477-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2018-03-01 | — | — | US | disclosed |
| WO-2017222083-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308628-B2 | Heterocyclic compounds and methods for their use | AGTR2, AGTR1, BDKRB2 | MAPT 2746/4885ALDH1A1 1943/4885GAA 3229/4885 |
| US-20220227699-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | AGTR2, AGTR1, AVPR2 | MAPT 3087/4885ALDH1A1 765/4885GAA 3024/4885 |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | AGTR2, AGTR1, AVPR2 | MAPT 482/4885ALDH1A1 1954/4885GAA 2970/4885 |
| US-20180057477-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | AGTR2, AGTR1, BDKRB2 | MAPT 2777/4885ALDH1A1 1904/4885GAA 3249/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | MAPT 1947/4885ALDH1A1 2233/4885GAA 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.